OCDEM’s Kate Lines awarded 3-year Celgene Fellowship

Kate Lines studied for a BSc in Biochemistry at Liverpool University, then a PhD in Molecular Oncology at the Barts Cancer Institute. During her PhD, Kate studied the molecular mechanisms of pancreatic ductal adenocarcinomas. Kate has been a postdoctoral research scientist in Rajesh Thakker’s laboratory (Academic Endocrine Unit) in OCDEM for 7 years, studying epigenetic mechanisms in pancreatic and pituitary neuroendocrine tumours and was recently awarded a 3-year Celgene Fellowship to investigate novel therapeutic strategies for this disease.

Pancreatic neuroendocrine tumours occur in pancreatic endocrine cells. These tumours can secrete hormones such as insulin and gastrin, and therefore can have significant endocrine morbidities, as well as the mortality associated with tumour development. There are currently limited effective treatments available for these patients, with the result being poor prognosis and a significant need to develop novel therapeutic strategies. The preferred first line treatment is surgery; however, this is not possible for all, especially those with multiple endocrine neoplasia type one (MEN1) who develop multiple tumours simultaneously. In addition, current chemotherapy approaches are often ineffective.

Kate’s research focuses on understanding the epigenetic mechanisms, particularly histone modifications, of pancreatic neuroendocrine tumours. Kate plans to identify novel compounds (and combinations thereof) that can target the altered epigenetic states of these tumours and develop novel medical treatments that will not only benefit patients who cannot undergo surgery, but may also provide a non-surgical option for patients with less aggressive tumours. Kate will be working closely with the Structural Genomics Consortium (Chas Bountra) in Oxford and Celgene for drug development and access, Medical University of Vienna (Dr Andreas Selberherr), Imperial College London (Prof Andrea Frillingand Oxford Hepatobilary and Pancreatic Surgery Department (Mr Zahir Soonawalla) for access to patient samples.

This research will be funded by the Oxford-Celgene fellowship. This fellowship provides a perfect opportunity to combine the expertise of both academia and industry. Through this collaboration Kate will have access to Celgene’s compound library, and state-of-the-art equipment for use with in vitro, in vivo and ex vivo pancreatic neuroendocrine models.

Find out more about our research below

Eoghan Mullholland awarded colorectal cancer fellowship

As part of UK Pride month, we are spotlighting the work of cancer researcher and University LGBTQ+ Representative Dr Eoghan Mulholland

New study investigates how growth factors in our gut could initiate cancer

Dr Francesco Boccellato is investigating the mechanisms of tissue regulation in the healthy stomach and in a pre-cancerous condition known as atrophic gastritis. This may help to identify those who may have cancer, as well as find new ways to prevent cancer from progressing

Understanding how cancer arises from infected tissue

Dr Francesco Boccellato is investigating the mechanisms behind the pre-cancerous condition known as atrophic gastritis. This may help to identify those who may have cancer, as well as find new ways to prevent cancer from progressing

Bowel cancer patients going undiagnosed due to COVID distruption

A new study led by the University of Oxford has found that since the first coronavirus lockdown the number of people diagnosed with bowel cancer in England has fallen sharply, with a deficit persisting up to October 2020

Bioengineering the human gut

An interdisciplinary collaboration generates an advanced model of the human gastrointestinal tract with broad applications for disease research and regenerative medicine
Image from an endoscopy video with the detected artefacts highlighted with coloured boxes.

Using AI to improve the quality of endoscopy videos

A multidisciplinary team of researchers has developed a deep-learning framework for improving endoscopy to aid cancer detection.

How chemotherapy impacts the body

A new study has investigated how chemotherapy impacts oesophageal cancer patients and if this determines a patient’s risk of post-operative complications

First Huaxi SCU-Oxford Forum on Gastrointestinal Cancer

The first Centre Forum was held in China this week, from 27-28th September 2020

Oxford University and Sichuan University form joint Centre for Gastrointestinal Cancer

The University of Oxford-Sichuan University Huaxi Joint Centre for Gastrointestinal Cancer is a new international collaboration that seeks to develop an integrated gastrointestinal cancer plan through the exchanging of ideas and resources.